Biotechnology

Carpmaels & Ransford has been at the forefront of the biotech industry from its inception

Biotechnology

An exceptional team trusted with the most important of biotech cases

Our Biotechnology team is recognised internationally for its breadth and depth of expertise. We have been at the forefront of the biotech industry since its inception. Now, as then, we are the first choice for top quality European IP advice. Our team is filled with specialist attorneys of unrivalled experience, who are supported by technical assistants of the highest calibre. We take pride in our accessibility, our responsiveness and in our bespoke strategic advice. We are a large team, and our collective experience is diverse. Together, we consistently deliver outstanding results for our clients.

Products on which our attorneys have worked in recent years include ABRAXANE®, ALOFISEL®, AVONEX®, BEXSERO®, DARZALEX®, DUPIXENT®, FLUCELVAX®, FORSTEO®, HUMIRA®, IDELVION®, LONQUEX®, PRALUENT®, RESPREEZA®, SIMPONI®, SPINRAZA®, STELARA®, TAKHZYRO®, TREMFYA®, WAYLIVRA®, and numerous others.

Whatever our client’s product or service, we offer an attorney or team who will understand the technology and its commercial context.

9
Partners
10
Senior Associates
9
Associates
7
Technical Assistants
October
2014

Successful defence of LEO Pharma’s patent opposed by multiple generics companies at the EPO

This event was particularly noteworthy because the same patent had been revoked only weeks before in the English High Court in Teva UK Ltd and Teva Pharmaceutical Industries Ltd v LEO Pharma A/S and LEO Laboratories Ltd [2014] EWHC 3096 (Pat).

Ultimately, the Court of Appeal followed the Opposition Division’s conclusions and overturned its lower Court.